文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

欧洲接受CAR-T细胞治疗的血液恶性肿瘤患者的患者报告结局

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.
PubMed 文献 · Blood Adv · 2025-01-01

该横断面研究于2023年1月至10月以7种语言在线调查了10个欧洲国家389例接受CAR-T治疗的血液恶性肿瘤患者,评估多维患者报告结局。患者总体健康相关生活质量与参照队列相似或更好,但角色、社交和认知功能存在问题,身体功能问题最常见(41%),焦虑常见,72%工作年龄患者可继续有偿工作,年轻患者经济困难更多。

要点

  • 389例欧洲CAR-T后患者中56%距治疗超过1年,平均EQ-VAS为73.1(标准差18.5)。
  • 身体功能问题最常见(41%),女性、老年人和经历神经毒性者更常报告。
  • 疾病复发焦虑(76%)、感染焦虑(66%)和长期副作用焦虑(59%)常见。

核心结论

  • 与参照队列相比,CAR-T后总体健康相关生活质量良好,但相当比例患者在身体、心理和社会健康方面存在问题。
  • 研究识别出高风险亚组和随访中应解决的照护需求。

研究设计与样本

  • 横断面研究,纳入10个欧洲国家389例接受CAR-T治疗的血液恶性肿瘤患者,56%距CAR-T超过1年。
  • 调查于2023年1月至10月以7种语言在线进行,使用经验证问卷(EQ-5D-5L、EORTC-QLQ-C30、PCL-5、改良iPCQ)及治疗体验、未满足照护需求和健康相关生活质量的临时条目。
  • 结局与欧洲一般人群、匹配的未接受CAR-T的血液恶性肿瘤队列及亚组比较,使用临床重要差异/问题的既定阈值和回归模型。

主要发现

  • 平均EQ-VAS为73.1(标准差18.5)。
  • 健康相关生活质量与参照队列相似或更好,但角色、社交和认知功能除外。
  • 身体功能问题最常报告(41%),尤其女性、老年人和经历神经毒性者;神经毒性亚组还报告更多认知和社交功能问题。
  • 疾病复发焦虑(76%)、感染焦虑(66%)和长期副作用焦虑(59%)常见。
  • 工作年龄患者中72%可在CAR-T后继续有偿工作;年轻患者(32%)比老年患者(9%)报告更多经济困难。

临床怎么用

  • 作者认为,随访中应解决所识别的高风险亚组和照护需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of life (HRQoL) and dimensions such as mental- and social well-being, working life, and financial burden. Therefore, we evaluated multidimensional PROs in a cross-sectional study among European patients who received CAR-T for hematologic malignancies. Patients completed validated questionnaires (EQ-5D-5L/EORTC-QLQ-C30/PCL-5/modified-iPCQ) and ad hoc items on treatment experiences, unmet care needs, and HRQoL. The survey was available online (January-October 2023) in 7 languages. Outcomes were compared with the European general population, a matched CAR-T-naive cohort with hematologic malignancies and across subgroups, using established thresholds for clinically important differences/problems and regression models. From 10 European countries, 389 patients participated (>1 year post-CAR-T: 56%). Mean EQ-VAS was 73.1 (standard deviation, 18.5). HRQoL was similar or better than reference cohorts, except for role-, social-, and cognitive-functioning. Physical-functioning problems were most frequently reported (41%), particularly by women, older individuals, and those who experienced neurotoxicity. The latter subgroup also reported more cognitive- and social-functioning problems. Anxiety regarding disease recurrence (76%), infections (66%) and long-term side effects (59%) was common. Among working-age patients, 72% could continue paid work after CAR-T. Younger patients (32%) reported more financial difficulties than older patients (9%). This study shows favorable general HRQoL after CAR-T compared with reference cohorts. However, a notable proportion of patients experienced problems in physical-, mental- and social well-being. We identified high-risk subgroups and care needs that should be addressed during follow-up.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pennings ERA, Spanjaart AM, Thielen FW, et al. Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood Adv. 2025. PMID: 40991391. doi:10.1182/bloodadvances.2025017081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。